GlaxoSmithKline PLC (ADR) (NYSE:GSK) Stock Upgrade
Bank of America (Merrill Lynch) gave GlaxoSmithKline PLC (ADR) (NYSE:GSK) shares a new Buy rating in a note issued to clients on 9 December. The raise from the old Neutral rating is certainly an interesting one.
From a total of 3 analysts covering GlaxoSmithKline (NYSE:GSK) stock, 1 rate it a ”Buy”, 0 a “Sell”, and 3 a ”Hold”. This means that 25% of the ratings are positive. The highest target price is $49 while the lowest target price is $43. The mean of all analyst targets is $45.67 with a 14.99% above today’s ($39.57) stock price. GlaxoSmithKline was the topic of 7 analyst reports since September 8, 2015 according to the firm StockzIntelligence Inc. Argus Research maintained shares on December 7 with “Buy” rating. JP Morgan upgraded GSK stock in a recent report from October 12 to “Neutral” rating. Finally, Bank of America upgraded the stock to “Neutral” rating in a report issued on a September 8.
Approximately 2.32M shares of stock traded hands. GlaxoSmithKline plc (ADR) (NYSE:GSK) has declined 14.17% since May 6, 2015 and is downtrending. It has underperformed by 13.37% the S&P500.
GlaxoSmithKline plc. is a healthcare firm that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The company has a market cap of $96.33 billion. The Firm operates in two divisions: Pharmaceuticals and Vaccines, and Consumer Healthcare. It has 6.48 P/E ratio. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.
According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.” Get a free copy of the Zacks research report on GlaxoSmithKline plc (ADR) (GSK).